Literature DB >> 20427505

Visually discernible [18F]fluorodeoxyglucose uptake in papillary thyroid microcarcinoma: a potential new risk factor.

Mijin Yun1, Tae-Woong Noh, Arthur Cho, Yun-Jung Choi, Soon-Won Hong, Cheong-Soo Park, Jong-Doo Lee, Chun K Kim.   

Abstract

CONTEXT: A significant number of papillary thyroid microcarcinomas (PTMCs), despite excellent prognosis, show aggressive features such as extrathyroidal extension (EE) and lymph node metastasis (LNM) that may not always be detected preoperatively or intraoperatively. The relapse rate appears also substantial.
OBJECTIVE: To assess the value of [(18)F]fluorodeoxyglucose (FDG) uptake in PTMC as a potential risk factor for preoperative risk stratification.
METHODS: This retrospective study included 87 patients (17 males and 70 females; mean age = 51.2 yr, range 29-74 yr) with a unifocal PTMC who underwent preoperative FDG-positron emission tomography (PET)/computed tomography (CT)and total thyroidectomy and central lymph node dissection. Statistical analyses were performed to compare the gender, age, tumor size, and FDG uptake in PTMC with the presence of histopathologically proven EE and central LNM (cLNM).
RESULTS: Of the 87 patients, 44 (51%) had EE, and 27 (31%) had cLNM. PET/CT showed visually discernible FDG uptake in 46 PTMCs (53%). FDG positivity of PTMCs was the only significant variable correlated with both EE and cLNM; there was a significant difference in the prevalence of both EE (70 vs. 29%) and cLNM (41 vs. 19.5%) between the FDG-positive and FDG-negative groups. In contrast, other already known risk factors, i.e. gender, age, and size, showed a correlation with only one or neither of EE and cLNM.
CONCLUSION: The results indicate that visual FDG positivity in PTMCs is a potential risk factor that can be useful for preoperative risk stratification. Prospective studies would be warranted to assess the long-term benefit and cost effectiveness of preoperative FDG-PET/CT.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20427505     DOI: 10.1210/jc.2009-2091

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  19 in total

1.  Rising incidence of thyroid cancer in Serbia.

Authors:  N Slijepcevic; V Zivaljevic; I Paunovic; A Diklic; Perisic Zivkovic; D Miljus; A Grgurevic; S Sipetic
Journal:  Hippokratia       Date:  2016 Jan-Mar       Impact factor: 0.471

2.  Feasibility of FDG-PET/CT for the initial diagnosis of papillary thyroid cancer.

Authors:  Heejin Kim; Kyung Jin Na; Jae Hyuk Choi; Byeong-Cheol Ahn; Dongbin Ahn; Jin Ho Sohn
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-05-14       Impact factor: 2.503

3.  Factors associated with positive F-18 flurodeoxyglucose positron emission tomography before thyroidectomy in patients with papillary thyroid carcinoma.

Authors:  Bum Soo Kim; Seong-Jang Kim; In Joo Kim; Kyounjune Pak; Keunyoung Kim
Journal:  Thyroid       Date:  2012-04-23       Impact factor: 6.568

4.  Correlation of BRAF mutation and SUVmax levels in thyroid cancer patients incidentally detected in 18F-fluorodeoxyglucose positron emission tomography.

Authors:  Aysenur Ozderya; Sule Temizkan; Aylin Ege Gul; Sule Ozugur; Mehmet Sargin; Kadriye Aydin
Journal:  Endocrine       Date:  2016-10-01       Impact factor: 3.633

5.  The relationship between lipotoxicity and risk of extrathyroidal extension in papillary thyroid microcarcinoma.

Authors:  Changlin Li; Haixia Guan; Qiao He; Yishen Zhao; Nan Liang; Jiao Zhang; Gianlorenzo Dionigi; Hui Sun
Journal:  Endocrine       Date:  2021-06-30       Impact factor: 3.633

6.  Association Between (18)F-FDG Avidity and the BRAF Mutation in Papillary Thyroid Carcinoma.

Authors:  Suk Hyun Lee; Sangwon Han; Hyo Sang Lee; Sun Young Chae; Jong Jin Lee; Dong Eun Song; Jin-Sook Ryu
Journal:  Nucl Med Mol Imaging       Date:  2015-09-22

7.  Clinical outcome, role of BRAF(V600E), and molecular pathways in papillary thyroid microcarcinoma: is it an indolent cancer or an early stage of papillary thyroid cancer?

Authors:  Carmelo Nucera; Alfredo Pontecorvi
Journal:  Front Endocrinol (Lausanne)       Date:  2012-02-27       Impact factor: 5.555

8.  The Role of 18F-Fluorodeoxyglucose Positron Emission Tomography in the Prognostication, Diagnosis, and Management of Thyroid Carcinoma.

Authors:  Brian Hung-Hin Lang
Journal:  J Thyroid Res       Date:  2011-10-09

9.  PTEN loss is associated with follicular variant of Middle Eastern papillary thyroid carcinoma.

Authors:  S Beg; A K Siraj; Z Jehan; S Prabakaran; S S Al-Sobhi; M Al-Dawish; F Al-Dayel; K S Al-Kuraya
Journal:  Br J Cancer       Date:  2015-05-19       Impact factor: 7.640

10.  Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors.

Authors:  Gabriella Pellegriti; Francesco Frasca; Concetto Regalbuto; Sebastiano Squatrito; Riccardo Vigneri
Journal:  J Cancer Epidemiol       Date:  2013-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.